An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof,
wherein R
1
is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R
2
is an acyl group, a thioacyl group, CONR
7
R
8
, or CSNR
7
R
8
(R
7
and R
8
being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R
1
and R
2
together may form a ring, X
1
and X
2
may be the same or different and are each —CR
3
R
4
—, —SiR
3
R
4
— or oxygen, and R
3
and R
4
may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.
一种提供成人T细胞白血病的新型治疗药物的对象是具有ATL细胞特异性抗肿瘤作用。根据本发明的成人T细胞白血病治疗药物的特征在于含有由式I表示的化合物或其前药,
其中R
1
为H、OH、烷氧基、酰基或硫酰基,R
2
为酰基、硫酰基、CONR
7
R
8
或CSNR
7
R
8
(R
7
和R
8
各自独立地为H、含有1至3个碳原子的烷基或苯基),或R
1
和R
2
可共同形成环,X
1
和X
2
可以相同也可以不同,分别为—CR
3
R
4
—、—SiR
3
R
4
—或氧,R
3
和R
4
可以相同也可以不同,分别为含有1至6个碳原子的烷基。
Therapeutic drug for adult T-cell leukemia
申请人:Baba Masanori
公开号:US08765719B2
公开(公告)日:2014-07-01
An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof,
wherein R1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R2 is an acyl group, a thioacyl group, CONR7R8, or CSNR7R8 (R7 and R8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R1 and R2 together may form a ring, X1 and X2 may be the same or different and are each —CR3R4—, —SiR3R4— or oxygen, and R3 and R4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.
An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof,
wherein R1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R2 is an acyl group, a thioacyl group, CONR7R8, or CSNR7R8 (R7 and R8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R1 and R2 together may form a ring, X1 and X2 may be the same or different and are each -CR3R4 -SiR3R4- or oxygen, and R3 and R4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.